Last update 24 Jun 2024

Spanlecortemlocel (Magenta Therapeutics)

Overview

Basic Info

Drug Type
Hematopoietic stem cell therapy
Synonyms
Cord blood stem cell therapy Novartis, Expanded umbilical cord blood Novartis, LFU835 expanded umbilical cord blood stem cells
+ [2]
Target-
Mechanism
Cell replacements
Therapeutic Areas
NeoplasmsImmune System DiseasesInfectious Diseases+ [2]
Active Indication
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaBurkitt Lymphoma+ [6]
Inactive Indication
Chronic Lymphocytic LeukemiaFollicular LymphomaGenetic Diseases, Inborn+ [3]
Originator Organization
Novartis AGNovartis AG
Active Organization
University of Minnesota Masonic Cancer Center
Inactive Organization
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp.Magenta Therapeutics, Inc.Magenta Therapeutics, Inc.
Drug Highest PhasePhase 2
First Approval Date-
Regulation-

Related

5
Clinical Trials associated with Spanlecortemlocel (Magenta Therapeutics)
NCT03674411 / Active, not recruitingPhase 2IIT
Single-Arm, Open Label, Interventional Phase II Clinical Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
NCT03406962 / CompletedPhase 2
A Phase 2, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of MGTA-456 in Patients With Inherited Metabolic Disorders (IMD) Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
NCT02715505 / WithdrawnPhase 1/2
A Single-arm, Open-label, Study to Evaluate the Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD) Undergoing Stem Cell Transplantation After Reduced Intensity Conditioning
100 Clinical Results associated with Spanlecortemlocel (Magenta Therapeutics)
Login to view more data
100 Translational Medicine associated with Spanlecortemlocel (Magenta Therapeutics)
Login to view more data
100 Patents (Medical) associated with Spanlecortemlocel (Magenta Therapeutics)
Login to view more data
100 Deals associated with Spanlecortemlocel (Magenta Therapeutics)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Myeloid LeukemiaPhase 2
US
University of Minnesota Masonic Cancer Center
02 Jan 2019
Burkitt LymphomaPhase 2
US
University of Minnesota Masonic Cancer Center
02 Jan 2019
Diffuse large B-cell lymphoma recurrentPhase 2
US
University of Minnesota Masonic Cancer Center
02 Jan 2019
Lymphoplasmacytic LymphomaPhase 2
US
University of Minnesota Masonic Cancer Center
02 Jan 2019
Mantle-Cell LymphomaPhase 2
US
University of Minnesota Masonic Cancer Center
02 Jan 2019
Philadelphia chromosome positive chronic myelogenous leukemiaPhase 2
US
University of Minnesota Masonic Cancer Center
02 Jan 2019
T-cell lymphoma recurrentPhase 2
US
University of Minnesota Masonic Cancer Center
02 Jan 2019
Genetic Diseases, InbornPhase 2
US
Magenta Therapeutics, Inc.
09 Feb 2018
Metabolic DiseasesPhase 2-
Novartis Pharmaceuticals Corp.
10 Oct 2017
Acute Lymphoblastic LeukemiaPhase 2
US
Novartis Pharmaceuticals Corp.
07 Oct 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03674411 (MGTA-456, CTgov)
Phase 2
Acute Myeloid Leukemia | Lymphoplasmacytic Lymphoma | Mantle-Cell Lymphoma ...
View more
22
glycvrtbff(tdniogdwvf) = bjijsskgyz kkdbncxfun (dcpvpnzicx, tgbxwmudvo - peokgawwtn)
View more
-
30 Jan 2024
NCT03406962 (IMD-001, CTgov)
Phase 2
Genetic Diseases, Inborn | Metabolic Diseases
8
altmhiemvy(gnlukmyytp) = gzidifxxla rnevfahvbv (kptgzlhbjm, kabpyidvnl - zcuzbsvicf)
View more
-
28 Oct 2021
P335 (EBMT2020)
Not Applicable
Peripheral Nervous System Diseases
-
bzwfioonhp(kvtmkvhgwv) = normalization of behavioral activity to wild type levels at 4 and 16 weeks post-HSCT ecvgtjxxuf (scxqmeprus )
Positive
29 Aug 2020
Low cell dose therapy
NCT03406962 (IMD-001, ASGCT2020)
Phase 2
Metabolic Diseases
-
Fresh MGTA-456
fhmjzrrgdw(eqjdroeqob) = zrcdfrfozf tjuyymlnzu (bentnetksb )
View more
Positive
28 Apr 2020
NCT03674411 (MGTA-456, ASGCT2020)
Phase 2
CD34 + CD90 +
17
gumpifvkom(midrzkmirw) = xcyhrrnxkd vqgepwwbay (rrdusrukle )
View more
Positive
28 Apr 2020
P4.6-059 (AAN2019)
Phase 2
Metabolic Diseases
12
horwazjfss(tdlzwcsifr) = Two patients developed autoimmune cytopenia, a known complication in IMD patients after HSCT, assessed as unrelated to MGTA-456 alnclsihfn (mvbnskjkxq )
Positive
09 Apr 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free